SEC Tracker
Get the app

Lomond Therapeutics Holdings

Lomond Therapeutics Holdings Q1 FY26: net loss $5.3M; diluted EPS −$0.16

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Lomond Therapeutics Holdings reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$5.3MAgainst −$6.2M in Q1 FY2510-Q income statement, on EDGAR
  2. Diluted EPS−$0.16Against −$0.21 in Q1 FY2510-Q income statement, on EDGAR
  3. Cash and cash equivalents$10.9M−71% from $37.6M in Q1 FY2510-Q balance sheet, on EDGAR
  4. Cash from operations−$4.5MAgainst −$705K in Q1 FY2510-Q cash flow statement, on EDGAR

View on EDGAR

Open in the app

Get an email when Lomond Therapeutics Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. America Great Health AAGH
  2. Nika Pharmaceuticals NIKA
  3. Regenerex Pharma RGPX
  4. CNBX Pharmaceuticals CNBX public float $252K, Aug 31, 2025
  5. NovAccess Global XSNX public float $338K, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.